Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055


News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.


-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at

Subscribe to WSJ:

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
React to this article
Latest news on MERCK & CO., INC.
03:19p MERCK : 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Co..
06:08aDJBayer Reiterates Plans to Divest Plastics Business -- 2nd Update
04:01aDJBayer Profit Falls Sharply as Costs Bite --Update
02:10aDJBayer Profit Falls Sharply as Costs Bite
02/25DJGeneric Copies of Remicade Go on Sale in Europe
02/25 MERCK : Researchers from Merck & Company Detail New Studies and Findings in the ..
02/25 Biosimilar copies of blockbuster drug launch in major EU markets
02/25 MERCK : New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and T..
02/24 MERCK : Announces Second-Quarter 2015 Dividend
02/24 MERCK : Announces Collaboration with the Medicines Patent Pool to Expand Access ..
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes